Dr. Eisenhauer is Head of the Department of Oncology at Queen’s University in Kingston, Ontario, and Program Medical Director of the Cancer Centre of Southeastern Ontario at Kingston General Hospital. She served as Chair of the Partnership’s Research Advisory Group during the organization’s first mandate at which time she was also co-chair of the Canadian Cancer Research Alliance, which brings together Canada’s major cancer research funders.
Dr. Eisenhauer received her medical degree from Queen’s University and completed the Royal College of Physicians and Surgeons of Canada’ training in internal medicine and hematology.
For 30 years, Dr. Eisenhauer was Director of the Investigational New Drug Program of the NCIC Clinical Trials Group where her major responsibilities lay in identifying and bringing into clinical trial novel cancer agents. She has served on many national and international cancer control bodies, receiving numerous awards recognizing her contribution to the field including the National Cancer Institute of Canada’s O. Harold Warwick Prize and the Presidential Medal Award from the Society of Gynecologic Oncology of Canada. Dr. Eisenhauer gave the New Drug Development Office (NDDO) Award Lecture at the international conference on Targeted Anti-Cancer Therapies in Amsterdam in 2012
Based on her demonstrated leadership, creativity, competence and commitment to the health sciences, in 2013, Dr. Eisenhauer was elected as a fellow of the Canadian Academy of Health Sciences (CAHS). Furthermore, based on her research contributions to health sciences, she was elected as a fellow of the Royal Society of Canada in 2015.
Areas of Expertise (7)
O. Harold Warwick Prize (professional)
National Cancer Institute of Canada
Presidential Medal Award (professional)
Society of Gynecologic Oncology of Canada
Queen’s University: MD, Medicine
- Canadian Cancer Research Alliance: Co-Chair
Media Appearances (3)
Can Endgame Tobacco radically reduce cigarette smoking?
Healthy Debate online
An estimated 100 Canadians die every day from tobacco-related causes.
“It’s something we’ve become immune to,” says Elizabeth Eisenhauer, an oncologist and co-chair of the Canadian Cancer Research Alliance. “That’s equivalent to a plane falling out of the sky every day. How many days would go by before the government closed down that airline?”...
...“The burden on smokers to fix this themselves has also been challenging because it isn’t their fault that this is happening,” Eisenhauer says. “Many long-term smokers tried cigarettes when they were as young as 14 years old. What informed choices does a 14-year-old make, really?”
Endgame’s proponents are still discussing which interventions might help reach the goal. But they’re also encouraging hospitals and clinicians to adapt the Ottawa Model for Smoking Cessation, which involves developing a system to consistently identify, treat and follow up with all patients who smoke.
“When they are captive in hospital because they’re ill, they’re already going to be a few days without smoking. It’s a great time to intervene,” Eisenhauer says.
The tobacco endgame: Radical proposals part of strategy to win faltering war on smoking
National Post online
Canada’s first tobacco-endgame “summit” is planned for Queen’s University in Kingston, Ont., this fall. It will be headed by Dr. Elizabeth Eisenhauer, the oncology department chairwoman, with about 100 invitation-only public-health and policy experts brainstorming a blueprint for dramatic action.
Cancer researchers upbeat at open house
The Kingston Whig-Standard online
In her closing remarks, Dr. Elizabeth Eisenhauer said that while it can appear as if little progress has been made to improve cancer therapies, the survival rate has improved. When the Canadian Cancer Society began in the 1930s, the survival rate was 25%, she said. It’s now edging near 65%.
Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1–3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer.
The phosphatidylinositol-3 kinase/serine–threonine kinase PI3K/AKT pathway is postulated to be central to cancer cell development. Activation of this pathway is believed to promote angiogenesis, protein translation and cell cycle progression. A large percentage of endometrial carcinomas have demonstrated mutations within this regulation pathway which result in constitutional activation. The downstream effector protein mammalian target of rapamycin (mTOR) acts as a critical checkpoint in cancer cell cycling and is a logical target for drug development. The efficacy and tolerability of the oral mTOR inhibitor ridaforolimus were evaluated in this study.
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is of increasing interest as a therapeutic strategy in many tumors. The aim of this study was to identify molecular markers associated with mTOR inhibitor activity in women with metastatic endometrial cancer.
We report a multicenter phase II study of patients with metastatic melanoma (MM), evaluating the efficacy, toxicity, progression-free survival (PFS), immunogenicity, and biomarker profile of interleukin-21 (IL-21).